NEW YORK, Oct. 24, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 70+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. To view the full publication, “Investors Turn to AI-Driven Imaging Firms Target ...

NEW YORK, Oct. 24, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 70+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. To view the full publication, “Investors Turn to AI-Driven Imaging Firms Target ...

NEW YORK, Oct. 22, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 70+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. To view the full publication, “Investors Eye Next-Gen 3D AI-Imaging Technologie ...

VANCOUVER, British Columbia, and SACRAMENTO, Calif., Oct. 08, 2025 (GLOBE NEWSWIRE) -- via IBN – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) (“Izotropic”, or the “Company”), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, marks Breast Cancer Awareness Month by underscoring the persistent limitations in current breast cancer imaging tools and the significant commer ...

VANCOUVER, British Columbia, and SACRAMENTO, Calif., Sept. 25, 2025 (GLOBE NEWSWIRE) -- via IBN – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) (“Izotropic”, or the “Company”), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, is pleased to announce the publication of a new feature article on BreastCT.com titled “AI Is Reshaping Breast Imaging, and IzoView Was Built f ...

VANCOUVER, British Columbia, and SACRAMENTO, Calif., Sept. 25, 2025 (GLOBE NEWSWIRE) -- via IBN – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) (“Izotropic”, or the “Company”), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, is pleased to announce the publication of a new feature article on BreastCT.com titled “AI Is Reshaping Breast Imaging, and IzoView Was Built f ...

核心技术进展 - 公司为其旗舰产品IzoView乳腺CT成像系统集成了一项新的专利待决辐射剂量个性化功能[1] - 该技术利用集成的无辐射光学预扫描系统和专有软件，实现实时定制辐射剂量，成为首个提供此功能的乳腺CT系统[1] - 光学预扫描系统通过捕获乳房的无辐射图像，为每位患者计算个性化的辐射剂量[2] - 该系统使用的剂量参考模型基于加州大学戴维斯分校医学中心超过20年的学术研究和临床试验数据开发[2] - 该功能消除了技术人员手动选择剂量的需求，简化了检查设置流程，有助于提升运营效率[3] 产品优势与市场定位 - IzoView系统结合了无压迫、无接触的设计以及个性化辐射剂量，旨在提升患者舒适度并支持在筛查和诊断环境中的依从性[3] - 该产品将个性化辐射剂量与专有的深度学习图像重建算法相结合，可在不增加辐射剂量的情况下优化图像，这与其它基于人工智能的方法不同[4] - 个性化医疗趋势正推动全球乳腺成像设备市场规模从2024年的54亿美元增长至2030年的86.9亿美元[4] - 市场增长由乳腺癌发病率上升、对致密乳腺组织女性进行补充筛查的报销范围扩大以及支持个性化成像协议和智能自动化的技术采用所驱动[4] 监管与商业化战略 - IzoView正通过美国FDA的上市前批准流程推进其明确的监管路径，并在今年早些时候通过预提交与机构就临床研究设计达成一致[5] - 公司准备在获得资金后启动其关键的美国临床研究，并计划利用在美国成像的前100名患者的数据提交欧洲CE标志申请[5] - 这种双路径策略旨在加速产品上市时间，同时在高价值的医疗保健区域建立IzoView的市场地位[5]

核心技术特点 - 专利待决的光学预扫描技术可实现根据患者独特乳房大小和密度定制的个性化辐射剂量 [1] - 该技术使IzoView成为首个提供实时定制辐射剂量的乳腺CT系统 无需技术人员手动选择剂量 有助于提高操作效率 [1][3] - 该功能与免压迫、非接触式设计相结合 旨在提升患者舒适度 并支持在筛查和诊断环境中的合规性 [3] 产品与市场定位 - 辐射剂量个性化功能已集成到IzoView商用机型中 同时具备模块化工程、AI驱动的图像优化等特点 [1] - 该技术顺应个性化医疗趋势 全球乳腺成像设备市场规模预计从2024年的54亿美元增长至2030年的86.9亿美元 [4] - 市场增长由乳腺癌发病率上升、对致密乳腺组织女性补充筛查的报销范围扩大以及支持个性化成像协议的技术采用所驱动 [4] 技术合作与监管进展 - 光学预扫描系统使用在加州大学戴维斯分校医学中心开发的剂量参考模型 该中心拥有超过20年的乳腺CT技术研究和临床试验经验 [2] - 公司拥有乳腺CT技术的全球独家权利 IzoView已被设计为商用设备模型 [2] - IzoView正通过美国FDA的上市前批准流程推进 并已在临床研究设计上与机构达成一致 准备在融资后启动关键的美国临床研究 [5] - 公司计划利用美国前100名患者成像数据提交欧洲CE标志申请 采用双路径策略加速进入高价值医疗保健区域市场 [5]

VANCOUVER, British Columbia, and SACRAMENTO, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) -- via IBN –Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) (“Izotropic”, or the “Company”), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces the launch of a new Frequently Asked Questions (“FAQ”) page on its corporate website. The new FAQ resource, available at www.izocorp.c ...

公司核心技术与产品 - Izotropic公司专注于商业化IzoView Breast CT成像系统 该系统旨在通过更精确的筛查、诊断和治疗手段改善乳腺癌检测效果 [2][3] - 该技术可检测小至2毫米的癌症病灶 而当前标准护理的平均检测尺寸为11毫米 意味着可提前12至18个月发现癌症 [4] - 公司近期宣布开发出独有的AI技术能力 该技术预计将随时间推移获得市场认可 [5] 商业化战略与市场定位 - 商业化策略分阶段在欧洲和美国推进 初期重点面向医院、医疗机构和影像诊所销售设备 [6] - 欧美市场合计占全球该类设备市场份额近50% [6] - 公司认为其可能成为大型企业的收购目标 因后者若希望维持市场份额需通过收购介入该领域 [5] 知识产权与竞争优势 - 公司通过专利组合、商业秘密和产品构建知识产权保护体系 [5] - 技术优势体现在对早期侵袭性癌症的检测能力上 当前标准护理在该领域存在显著不足 [4] 监管进展与市场机会 - 产品开发符合FDA标准 若获得FDA批准将打开全球市场机会 [3][6] - 目前正通过临床验证支持商业化进程 并已观察到显著早期需求 [5]